Explore this article's sources with AI
Follow PeptideMethods on Google
CJC-1295 Side Effects in Human Trials
Early CJC-1295 trials reported no serious reactions, but lacked a full public event table and cannot establish long-term safety.
Why we wrote this. Readers deserve the trial's narrow safety finding and FDA's warning without made-up event rates or a nonexistent label.
In this article (4 sections)
The published human CJC-1295 programme was small and short. Its abstract says no serious adverse reactions were reported and describes the long-acting compound as relatively well tolerated, particularly at the highlighted dose levels[1]. That is not the same as proving safety. The public abstract does not provide a complete adverse-event table or event rates, and the studies lasted 28 and 49 days.
The FDA now gives a more cautious compounding warning. It says compounded CJC-1295 may pose immunogenicity and peptide-impurity risks, and it identifies serious adverse events including increased heart rate and a systemic vasodilatory reaction. The agency also says clinical data are limited[2]. There is no FDA-approved CJC-1295 label with a boxed warning or a standardized adverse-event table.
What the early trials reported
Teichman and colleagues combined two randomized, placebo-controlled ascending-dose trials in healthy adults aged 21 to 61, with blinding used in both. One trial involved single administrations, and the other involved repeated weekly or every-two-week administrations. The investigators measured drug exposure and safety as well as growth hormone and IGF-1 over 28 or 49 days[1].
The abstract's safety statement is narrow: no serious adverse reactions were reported, and the compound was described as relatively well tolerated in that early programme[1]. It does not state how many participants had headache or flushing. It also omits rates for injection-site symptoms and other common events. Without a published denominator and event table in the inspected record, exact rates should not be invented.
A phrase such as 'no serious adverse reactions' only describes what happened in the observed sample and period. A small trial can miss uncommon harms, while short follow-up cannot characterize delayed problems in people whose cardiovascular, metabolic, endocrine, or immune conditions may differ sharply from those of screened healthy volunteers.
What FDA flags for compounded CJC-1295
FDA's safety-risk page says compounded drugs containing CJC-1295 may create an immunogenicity risk for certain routes. Immunogenicity means the immune system reacts to the substance. The agency also points to difficulties with peptide-related impurities and active-ingredient characterization[2]. These are product-quality concerns as well as molecule-level concerns.
On reported clinical events, FDA names increased heart rate and a systemic vasodilatory reaction[2]. Vasodilation is widening of blood vessels, which can contribute to flushing, light-headedness, or blood-pressure changes. The agency page does not provide event rates or separate long-acting CJC-1295 from material sold as no DAC. It therefore cannot support claims that both versions have identical risk profiles.
This distinction is relevant when readers report hives or flushing after a blend. Our CJC-1295 and ipamorelin hives guide explains why a reaction to a multi-ingredient vial cannot be assigned confidently to one peptide. Seek urgent medical help for breathing difficulty, swelling of the face or throat, fainting, or a rapidly worsening reaction.
Why there is no regulatory label to quote
The evergreen brief asks for late-stage trial rates and a regulatory label, but that template does not fit CJC-1295. The evidence inspected here is an early healthy-volunteer programme, not an approval trial. FDA has not published an approved prescribing label for CJC-1295. The agency's compounding page is a safety warning, not a product label and not an approval.
A 2026 sports-medicine review said that substantial safety and efficacy research is still needed before definitive recommendations can be made for popular injectable peptide approaches. It also said indications, dosing, frequency, and duration remain unknown[3]. For CJC-1295 combined with ipamorelin, the review found animal rather than controlled human combination evidence.
The CJC-1295 human-study dosing article keeps historical exposure figures in their research setting. The with-DAC versus without-DAC explainer covers why product names do not guarantee equivalent pharmacology.
The main CJC-1295 evidence page summarizes the molecule and its research status. The ipamorelin reference page covers the other ingredient commonly sold in blends. A reaction to a blend should not be assigned to either page without clinical evidence.
Side-effect reporting also depends on active follow-up. A checklist can capture a mild symptom that an open question misses, while a short observation period will not reveal delayed events. These design details are why one sentence in an abstract cannot support a ranked list of common and rare effects.
That limitation is easy to overlook when a short abstract is the only public summary being read, because the reassuring phrase is visible while the missing denominators, collection method, severity grades, timing, withdrawals, and follow-up boundaries are not presented beside it for readers to inspect.
What we do not yet know
The literature does not establish long-term safety, reliable event rates for common side effects, risks in people with chronic conditions, or the safety of repeated use outside a trial. It does not establish whether online products contain the studied molecule or what impurities they carry. The FDA warning does not identify a safe route, amount, or schedule.
Future trials would need a defined formulation, prespecified adverse-event collection, and enough participants and follow-up to estimate frequency. Public reports should also separate the albumin-binding compound from products marketed without DAC. Those data are not available in the sources inspected here.
Medical disclaimer: This article is for educational and journalistic purposes only and does not constitute medical advice. Peptides discussed may be classified as prescription medicines or research chemicals depending on your jurisdiction. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.
Frequently asked
What side effects did CJC-1295 trials report?
The main abstract says no serious adverse reactions were reported and describes the compound as relatively well tolerated. It does not provide a complete event table or rates for common events.
Does CJC-1295 have an FDA boxed warning?
There is no FDA-approved CJC-1295 prescribing label, so there is no product label or boxed warning to quote. FDA instead lists safety concerns for compounded CJC-1295.
What serious reactions has FDA identified?
FDA identifies increased heart rate and a systemic vasodilatory reaction, while noting limited clinical data. Its page does not provide event rates.
Are CJC-1295 with DAC and no DAC equally risky?
The available FDA warning does not separate them, so it cannot show identical risk profiles. Different molecule identity and uncertain product quality prevent a simple equivalence claim.
Sources
- [1]Teichman et al. (2006): Safety and hormone responses to CJC-1295 (PMID 16352683)Tier 1 · primary↩
- [2]FDA: Compounded CJC-1295 safety risksTier 1 · primary↩
- [3]Mayfield et al. (2026): Injectable peptide therapy evidence review (PMID 41476424)Tier 1 · primary↩
No revisions yet. First published .